MSH6 and colorectal carcinoma: Compared with CRC in the general population, therapy related CRC showed more frequent loss of MSH2/MSH6 staining (13% vs 1%, P < 0.001) and a higher MSI frequency (24% vs 11%, P = 0.003) [35].